Alnylam Pharmaceuticals

Alnylam Pharmaceuticals develops novel therapeutics-based RNAi and provides overviews of recent drug development programs.


Alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as RNA interference, or RNAi. With RNAi technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Founders:  David Bartel, John Clarke, Paul Schimmel, Phillip D. Zamore, Phillip Sharp, Robert Langer, Thomas Tuschl